Asem Werdi, MD
Hospitalist · Oak Lawn, ILNPI 1588953038
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $629 and has fallen 95.5% since, to $28 in 2025. Among hospitalist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$395
- Novartis$256
- AbbVie$178
- Mannkind Corporation$133
- Sanofi-aventis U.S. LLC$110
- Lilly USA, LLC$108
- plus $939 from 30 others
What the payments were for
- Food & beverage$2,10899%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $395 |
| Novartis | 13 | $256 |
| AbbVie(2 entities) | 8 | $178 |
| Mannkind Corporation | 7 | $133 |
| Sanofi-aventis U.S. LLC | 6 | $110 |
| Lilly USA, LLC | 5 | $108 |
| Amarin Pharma, Inc. | 4 | $85 |
| Bayer | 3 | $73 |
| AstraZeneca | 4 | $71 |
| Novo Nordisk | 4 | $70 |
| Shire North American Group Inc | 3 | $50 |
| Pfizer | 3 | $47 |
| Lundbeck LLC | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| IBSA Pharma Inc. | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 3 | $36 |
| Corcept Therapeutics | 2 | $31 |
| Dexcom, Inc. | 1 | $30 |
| Ardelyx, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Roche Diabetes Care, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Amgen | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Intuity Medical Inc | 1 | $14 |
| Abbott | 1 | $12 |
| Theracosbio, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$339
How this compares
$2,120 in reported general payments places this provider in the 95th percentile of 1,328 hospitalist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 812 | $226,063 |
| JardianceEmpagliflozin | 68 | $46,177 |
| JanuviaSitagliptin Phosphate | 44 | $30,769 |
| OzempicSemaglutide | 24 | $29,584 |
| TrulicityDulaglutide | 36 | $27,194 |
| EntrestoSacubitril/Valsartan | 85 | $25,358 |
| MounjaroTirzepatide | 23 | $23,951 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $23,209 |
| FarxigaDapagliflozin Propanediol | 38 | $20,847 |
| CaplytaLumateperone Tosylate | 17 | $15,765 |
| TradjentaLinagliptin | 34 | $13,692 |
| Sevelamer Carbonate | 154 | $13,232 |
| Atorvastatin Calcium | 1,374 | $11,831 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,246 |
| MyrbetriqMirabegron | 37 | $10,847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $47 | $226,063812 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $108 | $51,14559 claims |
| AstraZenecaLokelma, Farxiga | $71 | $44,05773 claims |
| Novo NordiskOzempic | $70 | $29,58424 claims |
| NovartisEntresto | $256 | $25,35885 claims |
| AbbVieCreon | $178 | $8,31317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,328 hospitalist providers in Illinois.
Other hospitalist in Oak Lawn
- Odulola OdusanyaLibertyville$544K
- Salih SamoChicago$251K
- Eric GluckChicago$80K
- Jorge Gomez AlarconLake Forest$72K
- Alvin ThomasChicago$28K
- Osman QaiyumMount Vernon$22K
- Wajahat HumayunMaywood$20K
- Gabriel DiazMaywood$18K
- Tasmeen HussainChicago$18K
- Juan Pablo Salazar AdumEvanston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.